ArticleJournal of virology2009
The marburg virus 3' noncoding region structurally and functionally differs from that of ebola virus.
Article in Journal of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Therapeutic advances in Marburg virus disease: from experimental treatments to vaccine development.Annals of medicine and surgery (2012) · 2025Review
- Recovery of Recombinant Marburg Virus by Reverse Genetics.Methods in molecular biology (Clifton, N.J.) · 2025Article
- How does the polymerase of non-segmented negative strand RNA viruses commit to transcription or genome replication?Journal of virology · 2024Review
- Phylogenetic analysis of the promoter element 2 of paramyxo- and filoviruses.Microbiology spectrum · 2024Article
- A paramyxovirus-like model for Ebola virus bipartite promoters.PLoS pathogens · 2020Article
- Distinct Genome Replication and Transcription Strategies within the Growing Filovirus Family.Journal of molecular biology · 2019Review
- Bipartite promoters and RNA editing of paramyxoviruses and filoviruses.RNA (New York, N.Y.) · 2019Review
- Article
- Small molecules targeting viral RNA.Wiley interdisciplinary reviews. RNA · 2016Review
- Marburg Virus Reverse Genetics Systems.Viruses · 2016Review
- Analysis of the highly diverse gene borders in Ebola virus reveals a distinct mechanism of transcriptional regulation.Journal of virology · 2014Article
- Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA.Archives of virology · 2014Article
- Article
- Structural basis for Marburg virus VP35-mediated immune evasion mechanisms.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Forty-five years of Marburg virus research.Viruses · 2012Review
- Recombinant Marburg virus expressing EGFP allows rapid screening of virus growth and real-time visualization of virus spread.The Journal of infectious diseases · 2011Article
- Filoviral immune evasion mechanisms.Viruses · 2011Review
- Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses.Antiviral research · 2011Review
- Marburg virus evades interferon responses by a mechanism distinct from ebola virus.PLoS pathogens · 2010Article
- Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain.Journal of virology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have previously shown that the first transcription start signal (TSS) of Zaire Ebola virus (ZEBOV) is involved in formation of an RNA secondary structure regulating VP30-dependent transcription activation. Interestingly, transcription of Marburg virus (MARV) minigenomes occurs independently of VP30. In this study, we analyzed the structure of the MARV 3' noncoding region and its influence on VP30 necessity. Secondary structure formation of the TSS of the first gene was experimentally determined and showed substantial differences from the structure formed by the ZEBOV TSS. Chimeric MARV minigenomes mimicking the ZEBOV-specific RNA secondary structure were neither transcribed nor replicated. Mapping of the MARV genomic replication promoter revealed that the region homologous to the sequence involved in formation of the regulatory ZEBOV RNA structure is part of the MARV promoter. The MARV promoter is contained within the first 70 nucleotides of the genome and consists of two elements separated by a spacer region, comprising the TSS of the first gene. Mutations within the spacer abolished transcription activity and led to increased replication, indicating competitive transcription and replication initiation. The second promoter element is located within the nontranslated region of the first gene and consists of a stretch of three UN(5) hexamers. Recombinant full-length MARV clones, in which the three conserved U residues were substituted, could not be rescued, underlining the importance of the UN(5) hexamers for replication activity. Our data suggest that differences in the structure of the genomic replication promoters might account for the different transcription strategies of Marburg and Ebola viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.